Agios Pharm

NASDAQ AGIO

Data sourced from

and

Download Data

Agios Pharm Tangible Asset Value Ratio for the Trailing 12 Months (TTM) ending March 31, 2024

Agios Pharm Tangible Asset Value Ratio is NA for the Trailing 12 Months (TTM) ending March 31, 2024. The tangible asset value ratio measures the proportion of tangible assets to total assets. It is calculated by dividing the tangible assets by the total assets. This ratio indicates the significance of tangible assets, such as property, plant, and equipment, in the company's total asset structure. A higher ratio suggests a higher proportion of tangible assets relative to total assets.

Agios Pharm Tangible Asset Value Ratio for the Trailing 12 Months (TTM) ending March 31, 2023 was 0.91, a 0.47% change year over year.
Agios Pharm Tangible Asset Value Ratio for the Trailing 12 Months (TTM) ending March 31, 2022 was 0.91, a 45.48% change year over year.
Agios Pharm Tangible Asset Value Ratio for the Trailing 12 Months (TTM) ending March 31, 2021 was 0.62, a -11.69% change year over year.
Agios Pharm Tangible Asset Value Ratio for the Trailing 12 Months (TTM) ending March 31, 2020 was 0.71, a -11.76% change year over year.

NASDAQ: AGIO

Agios Pharm

CEO	Dr. Bruce D. Car DACVP, Ph.D.
IPO Date	July 24, 2013
Location	United States
Headquarters	88 Sidney Street, Cambridge, MA, United States, 02139-4169
Employees	383
Sector	Healthcare
Industry	Biotechnology

Description

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Key trends